Abstract 2529
Background
Compared with quantification of messenger RNA, a protein level quantification allows for more relevant clinical outcome predictions and the identification of potential therapeutic targets. The aim of this study was to identify a novel protein level signature that was associated with overall survival in patients with resected pancreatic ductal adenocarcinoma (PDAC).
Methods
Data of 105 patients with resected PDAC were retrieved from TRGAted. Reverse-phase protein array (RPPA) quantification data of 218 proteins were collected. By using the LASSO regression model, a protein-level-based classifier was built. Time-dependent receiver operating characteristic (ROC) analysis was used to assess the prognostic accuracy of the classifier. Survival curves were compared by using the Kaplan-Meier analysis.
Results
Using the LASSO model, we built a classifier based on four proteins: BAK, IGFBP2, PDL1, and BRAF-pS445. Survival analysis revealed IGFBP2 and BRAF-pS445 were two favourable prognostic markers, and BAK and PDL1 were unfavourable prognostic markers. Using the classifier, we were able to classify patients between those at high risk of disease progression (high-risk group) and those at low risk of disease progression (low-risk group). Progression-free survival was significantly different between these two groups (11.7 vs 19.9 months for high-risk and low-risk groups, respectively; P < 0.0001). The median overall survival was 13.1 and 36.7 months for the high-risk and low-risk groups, respectively (hazard ratio [HR]: 4.09; 95% CI: 2.39 - 6.98; P < 0.0001). Five-year survival rate was 0% for the high-risk group, and 46% for the low-risk group. The prognostic accuracy (area under the ROC curve) of the classifier were 0.75, 0.77, and 0.81 at 1, 3, and 5 years, respectively. Multivariate Cox regression analysis showed that the classifier was an independent prognostic factor (P < 0.0001).
Conclusions
This protein-level classifier is a novel prognostic tool in patients with resected PDAC. It may facilitate individualized management of patients with this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jie Hua.
Funding
The National Science Fund for Distinguished Young Scholars of China (grant number 81625016).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY
Presenter: Maria Agnese Fabbri
Session: Poster Display session 2
Resources:
Abstract
4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
Presenter: Maysa Vilbert
Session: Poster Display session 2
Resources:
Abstract
5627 - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Presenter: Sabela Recalde
Session: Poster Display session 2
Resources:
Abstract
3917 - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients
Presenter: Mariana Chavez Mac Gregor
Session: Poster Display session 2
Resources:
Abstract
2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer
Presenter: Laura Spring
Session: Poster Display session 2
Resources:
Abstract
581 - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index
Presenter: Mohammad Hojouj
Session: Poster Display session 2
Resources:
Abstract
5327 - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
Presenter: Silvia Mihaela Ilie
Session: Poster Display session 2
Resources:
Abstract
3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.
Presenter: Lorenzo Livi
Session: Poster Display session 2
Resources:
Abstract
3736 - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.
Presenter: Icro Meattini
Session: Poster Display session 2
Resources:
Abstract
5085 - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Presenter: Isabel Blancas López-Barajas
Session: Poster Display session 2
Resources:
Abstract